First Horizon Advisors’s PTC Therapeutics PTCT Stock Holding History

First Horizon Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-111	Closed	-$4.51K	–	2486
2023 Q2	$4.51K	Hold	111	–	–	﹤0.01%	1824
2023 Q1	$5.38K	Buy	111 +27	+32%	+$1.23K	﹤0.01%	1791
2022 Q4	$3.21K	Sell	84 -89	-51%	-$3.7K	﹤0.01%	1924
2022 Q3	$9K	Buy	173 +1	+0.6%	+$49	﹤0.01%	1561
2022 Q2	$7K	Sell	172 -75	-30%	-$2.63K	﹤0.01%	1722
2022 Q1	$9K	Buy	247 +2	+0.8%	+$77	﹤0.01%	1141
2021 Q4	$10K	Hold	245	–	–	﹤0.01%	1522
2021 Q3	$9K	Hold	245	–	–	﹤0.01%	1574
2021 Q2	$10K	Buy	245 +2	+0.8%	+$86	﹤0.01%	1352
2021 Q1	$12K	Buy	243 +28	+13%	+$1.66K	﹤0.01%	1243
2020 Q4	$13K	Buy	215 +31	+17%	+$1.83K	﹤0.01%	1013
2020 Q3	$9K	Hold	184	–	–	﹤0.01%	1040
2020 Q2	$9K	Buy	184 +15	+9%	+$737	﹤0.01%	1049
2020 Q1	$8K	Buy	+169	New	+$8.51K	﹤0.01%	1002

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

First Horizon Advisors's PTCT Position: Q3 2023 in Review

First Horizon Advisors sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 111 shares — an estimated $4.51K sold.

First Horizon Advisors first reported a position in PTCT in Q1 2020 and held it in 14 quarters. The position peaked at $13K in Q4 2020. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

First Horizon Advisors reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
First Horizon Advisors sold 111 PTC Therapeutics shares in Q3 2023, an estimated $4.51K.
First Horizon Advisors first reported a position in PTC Therapeutics in Q1 2020 and held it in 14 quarters.
First Horizon Advisors's PTC Therapeutics position peaked at $13K in Q4 2020.
179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on First Horizon Advisors's 13F filing for Q3 2023, filed 27 Oct 2023.